Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Emergent Biosolutions Inc (NYSE: EBS) closed at $5.88 in the last session, up 0.68% from day before closing price of $5.84. In other words, the price has increased by $0.68 from its previous closing price. On the day, 0.99 million shares were traded.
Ratios:
We take a closer look at EBS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.09 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.38. For the most recent quarter (mrq), Quick Ratio is recorded 3.51 and its Current Ratio is at 6.32. In the meantime, Its Debt-to-Equity ratio is 1.22 whereas as Long-Term Debt/Eq ratio is at 1.21.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On August 22, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $16.
The Benchmark Company Upgraded its Hold to Buy on March 07, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 12 ’25 when Fowler Neal Franklin sold 35,000 shares for $5.83 per share. The transaction valued at 204,050 led to the insider holds 101,100 shares of the business.
Zoon Kathryn C sold 10,000 shares of EBS for $57,300 on Mar 12 ’25. The Director now owns 44,482 shares after completing the transaction at $5.73 per share. On Mar 12 ’25, another insider, Fowler Neal Franklin, who serves as the Director of the company, bought 35,000 shares for $5.83 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.33 while its Price-to-Book (P/B) ratio in mrq is 0.58.
Stock Price History:
Over the past 52 weeks, EBS has reached a high of $15.10, while it has fallen to a 52-week low of $4.02. The 50-Day Moving Average of the stock is 12.51%, while the 200-Day Moving Average is calculated to be -27.80%.
Shares Statistics:
A total of 54.50M shares are outstanding, with a floating share count of 51.95M. Insiders hold about 4.29% of the company’s shares, while institutions hold 65.35% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 2.0 analysts. The consensus estimate for the next quarter is -$0.26, with high estimates of $0.24 and low estimates of -$0.76.
Analysts are recommending an EPS of between $0.75 and $0.68 for the fiscal current year, implying an average EPS of $0.71. EPS for the following year is -$1.32, with 1.0 analysts recommending between -$1.32 and -$1.32.
Revenue Estimates
According to 3 analysts, the current quarter’s revenue is expected to be $174M. It ranges from a high estimate of $229M to a low estimate of $105M. As of the current estimate, Emergent Biosolutions Inc’s year-ago sales were $254.7MFor the next quarter, 3 analysts are estimating revenue of $186.67M. There is a high estimate of $225M for the next quarter, whereas the lowest estimate is $129M.
A total of 3 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $850M, while the lowest revenue estimate was $800.2M, resulting in an average revenue estimate of $819.51M. In the same quarter a year ago, actual revenue was $1.04BBased on 2 analysts’ estimates, the company’s revenue will be $951.08M in the next fiscal year. The high estimate is $1.2B and the low estimate is $707.15M.
